Contrast-enhanced digital mammography comparable to breast MRI
Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers at the recently held 2017 San Antonio Breast Cancer Symposium. “Our 
study aimed to compare contrast-enhanced mammography with breast MRI in evaluating residual breast cancer in patients undergoing presurgical systemic treatment to shrink their tumor size,” says Bhavika Patel, M.D., a radiologist at Mayo Clinic’s Arizona campus. “We identified patients who had both contrast-enhanced digital mammography and MRI after treatment to shrink their tumors and before additional therapy or a mastectomy.”
Reach: The Atlanta Journal-Constitution has a daily circulation of more than 142,640 and its website has more than 11.8 million unique visitors each month.
Context: Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium. “Our study aimed to compare contrast-enhanced mammography with breast MRI in evaluating residual breast cancer in patients undergoing presurgical systemic treatment to shrink their tumor size,” says Bhavika Patel, M.D., a radiologist at Mayo Clinic's Arizona campus. “We identified patients who had both contrast-enhanced digital mammography and MRI after treatment to shrink their tumors and before additional therapy or a mastectomy.” More information about the study can be found on Mayo Clinic News Network.
Tags: 2017 San Antonio Breast Cancer Symposium, Atlanta Journal-Constitution, digital mammography, Dr. Bhavika Patel, Uncategorized